Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 17/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685209 | 1.00 | KCNA3 (1.00) | KCNA3MEN1KMT2AALDH1A1 | |
| SCHEMBL3897406 | 0.89 | KCNA3 (0.81) | KCNA3MEN1KMT2AALDH1A1 | |
| SCHEMBL3455503 | 0.89 | MEN1 (1.00) | KCNA3MEN1KMT2AALDH1A1 | |
| SCHEMBL3911223 | 0.88 | KCNA3 (1.00) | KCNA3MEN1KMT2AALDH1A1 | |
| SCHEMBL3900579 | 0.88 | KCNA3 (0.79) | KCNA3MEN1KMT2AALDH1A1 | |
| SCHEMBL3904049 | 0.88 | MEN1 (0.97) | KCNA3MEN1KMT2AALDH1A1 | |
| SCHEMBL3908264 | 0.87 | MEN1 (0.79) | KCNA3MEN1KMT2AALDH1A1 | |
| SCHEMBL26627233 | 0.87 | KCNA3 (1.00) | KCNA3MEN1KMT2AALDH1A1 | |
| SCHEMBL3908721 | 0.86 | KCNA3 (0.76) | KCNA3MEN1KMT2AALDH1A1 | |
| SCHEMBL6437618 | 0.86 | MEN1 (0.80) | KCNA3MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289837-A1 | MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS | UNIV LJUBLJANI (SI) | 2025-09-18 | — | — | US | disclosed |
| EP-4511125-A1 | MITOCHONDRIOTROPIC BENZAMIDE POTASSIUM CHANNEL K1.3 INHIBITORS | Univerza V Ljubljani (SI) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023203185-A1 | MITOCHONDRIOTROPIC BENZAMIDE POTASSIUM CHANNEL K V1.3 INHIBITORS | UNIVERZA V LJUBLJANI (SI) | 2023-10-26 | — | — | WO | disclosed |
| US-8357704-B2 | Fused heterocyclic compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357704-B2 | Fused heterocyclic compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-7772232-B2 | Quinazolinyl compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1126836-B1 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-6632836-B1 | To treat autoimmune disorders, cardiac arrhythmias and the like | MERCK & CO., INC. | 2003-10-14 | — | — | US | disclosed |
| EP-1143965-A4 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1126836-A4 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1143965-A1 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1126836-A1 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6194458-B1 | 1-(2-METHOXYPHENYL)-1-OXO-2-AZA-(S)-4-I-BUTYL-4-PHENYLBUTANE, FOR EXAMPLE; TREATING VARIOUS CONDITIONS INCLUDING TRANSPLANTATION REJECTION OF ORGANS OR TISSUES IN A PATIENT; IMMUNOSUPPRESSANT COMPOSITIONS | MERCK & CO., INC. | 2001-02-27 | — | — | US | disclosed |
| WO-2000025774-A1 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000025770-A1 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289837-A1 | MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS | KCNJ2, KCNN3, KCNA3 | KCNA3 3/4885MEN1 1616/4885KMT2A 561/4885 |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNH2, KCNH3, KCNB1 | KCNA3 8/4885MEN1 544/4885KMT2A 641/4885 |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | HCAR2, HCAR1, SCN7A | KCNA3 114/4885MEN1 3541/4885KMT2A 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.